Probiotic *Escherichia coli* Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity

Sya N. Ukena1,2, Anurag Singh3, Ulrike Dringenberg3, Regina Engelhardt3, Ursula Seidler3, Wiebke Hansen1, André Bleich5, Dunja Bruder5, Anke Franzke7, Gerhard Rogler6, Sebastian Suerbaum2, Jan Buer7, Florian Gunzer6, Astrid M. Westendorf1

1 Department of Mucosal Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany, 2 Department of Haematology, Haemostaseology and Oncology, Hannover Medical School, Hannover, Germany, 3 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, 4 Institute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany, 5 Immune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany, 6 Department of Internal Medicine, Gastroenterological and Hepatology Unit, University Hospital of Zurich, Zurich, Switzerland, 7 Institute of Medical Microbiology, University Hospital Essen, Essen, Germany, 8 Faculty of Medicine Carl Gustav Carus, Institute for Medical Microbiology and Hygiene, Technology University (TU) Dresden, Dresden, Germany

Background. Probiotics are proposed to positively modulate the intestinal epithelial barrier formed by intestinal epithelial cells (IECs) and intercellular junctions. Disruption of this barrier alters paracellular permeability and is a key mechanism for the development of enteric infections and inflammatory bowel diseases (IBDs). Methodology and Principal Findings. To study the *in vivo* effect of probiotic *Escherichia coli* Nissle 1917 (EcN) on the stabilization of the intestinal barrier under healthy conditions, germfree mice were colonized with EcN or K12 *E. coli* strain MG1655. IECs were isolated and analyzed for gene and protein expression of the tight junction molecules ZO-1 and ZO-2. Then, in order to analyze beneficial effects of EcN under inflammatory conditions, the probiotic was orally administered to BALB/c mice with acute dextran sodium sulfate (DSS) induced colitis. Colonization of gnotobiotic mice with EcN resulted in an up-regulation of ZO-1 in IECs at both mRNA and protein levels. EcN administration to DSS-treated mice reduced the loss of body weight and colon shortening. In addition, infiltration of the colon with leukocytes was ameliorated in EcN inoculated mice. Acute DSS colitis did not result in an anion secretory defect, but abrogated the sodium absorptive function of the mucosa. Additionally, intestinal barrier function was severely affected as evidenced by a strong increase in the mucosal uptake of Evans blue *in vivo*. Concomitant administration of EcN to DSS treated animals resulted in a significant protection against intestinal barrier dysfunction and IECs isolated from these mice exhibited a more pronounced expression of ZO-1. Conclusion and Significance. This study convincingly demonstrates that probiotic EcN is able to mediate up-regulation of ZO-1 expression in murine IECs and confer protection from the DSS colitis-associated increase in mucosal permeability to luminal substances.

INTRODUCTION

The epithelial layer of the gastrointestinal tract serves as one of the primary interfaces with the outside world. The mucosal surface of the intestinal epithelium is in constant contact with abundant populations of microbes and their metabolites. The intestinal barrier formed by the epithelial cells and the junctional complex, consisting of tight junctions (TJ), adherens junctions, gap junctions and desmosomes, excludes the majority of these microbes and their metabolites from access to the subepithelial cells. Its effectiveness and stability are ensured by the junctional complex [1]. Compromising the integrity of this barrier can promote manifestation of enteric infections and is a key feature of IBDs like Crohn’s disease (CD) and ulcerative colitis (UC). Intestinal permeability was also found to be increased in HIV infection [2], and diarrhea is one of the most predominant symptoms of HIV-infected patients. The diarrhea of these patients is mainly due to infections with enteropathogens. However, in a number of HIV patients with gastrointestinal complaints no enteropathogen can be identified [3,4]. The role of a ‘leaky gut’ in the pathogenesis of gastrointestinal diseases is increasingly recognized. Consequently, reduction of the increased permeability is an interesting target for improvement of the clinical status of gastrointestinal diseases. Tight junctions are intricate macromolecular protein structures located at the most apical regions of the junctional complex, sealing the spaces between the IECs. The first junction-associated protein identified was zonula occludens 1 (ZO-1), with a molecular mass between ~210–225 kDa [5]. This molecule constitutes the structural link between the cytoskeleton and the tight junction by binding to both actin filaments and the TJ protein occludin [6]. Reorganization of TJ proteins like ZO-1, triggered by cytokines produced secondary to the inflammatory processes in IBDs, results in increased intestinal permeability [7,8]. ZO-2 is another TJ associated protein that forms a complex together with ZO-1 [9] and has recently been shown to be up-regulated by EcN in *in vitro* [10].

Probiotics are defined as live microorganisms which, when administered in adequate amounts, confer health benefits to the host [11]. The use of such microorganisms as novel therapeutic agents and as an alternative to standard medication in gastrointestinal diseases is promising, although their mechanism of action is still under investigation. EcN has evolved into one of the best

* To whom correspondence should be addressed. E-mail: Florian.Gunzer@tu-dresden.de

Academic Editor: Debbie Fox, The Research Institute for Children, United States of America

Received September 17, 2007; Accepted November 21, 2007; Published December 12, 2007

Copyright: © 2007 Ukena et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Supported by grants from the Deutsche Forschungsgemeinschaft (SFB 621).

Competing Interests: The authors have declared that no competing interests exist.
characterized probiotics, and its therapeutic efficacy and safety have convincingly been proven [12–16]. A potential mechanism by which probiotics may exhibit their beneficial activities is modulation of the epithelial barrier function [17,18]. This hypothesis is also supported by a recent study demonstrating that probiotic Streptococcus thermophilus and Lactobacillus acidophilus can prevent invasion of enteroinvasive E. coli and enhance intestinal epithelial barrier function by amplifying phosphorylation of occludin and ZO-1 in vitro [19].

Driven by mounting evidence affirming the beneficial effects of probiotics on the intestinal epithelial barrier and the already well-documented therapeutic efficacy of EcN, we set out to investigate the impact of EcN on the intestinal epithelial barrier function in vivo.

**MATERIALS AND METHODS**

**Mice**

All mice used in this study were 6–8 weeks old females. Conventional BALB/c mice were obtained from Harlan (Borchen, Germany). Gnotobiotic BALB/c mice were obtained from colonies maintained germfree at the Central Animal Facility of Hannover Medical School, as described previously [20]. The animal experiments reported here were conducted in accordance with the German Animal Welfare Law and with the European Communities Council Directive 86/609/EEC for the protection of animals used for experimental purposes. All experiments were approved by the local institutional animal care and research advisory committee and authorized by the district authority of Braunschweig and Hannover.

**Bacterial colonization of gnotobiotic BALB/c mice**

EcN or E. coli MG1655 was freshly grown to an OD600nm = 1 (~0.8–1.2×10^9 CFU/ml) from an overnight culture diluted 1:500 in LB media [21]. Bacteria were collected by centrifugation (1 ml, 3 min at 10000 g). The resulting pellet was resuspended in 200 μl sterile PBS and administered by oral gavage. Application was repeated two days later. After 6 days of colonization, fecal CFU were determined by plate count from pooled stool samples and were calculated per gram feces. The animals grew comparable numbers of both bacterial strains in all experiments averaging 5.8×10^9 CFU/g feces with EcN and 5.1×10^9 CFU/g feces with E. coli MG1655. Feces of mice that had received PBS remained sterile.

**Induction of colitis**

Acute colitis was induced in BALB/c mice by addition of 4–6% dextran sodium sulfate (DSS) (MP Biomedicals, Eschwege, Germany) to drinking water for a period of 8 days, according to a protocol recently described by Grabig et al. [22]. Animals were separated into the following groups: Group I was treated orally with PBS two times a day. Group II received drinking water with 4–6% DSS and was treated orally with PBS twice daily. Group III also received drinking water with 4–6% DSS and was given 1.5–2×10^9 CFU (Mutaflor mite, Ardeypharm, Germany) EcN twice daily by oral application (DSS+EcN) (Figure 1). Colitis induction was indicated by weight loss of the mice was monitored by comparing the body weight upon DSS treatment to the initial body weight of the respective animals.

**Isolation of IECs**

IECs were isolated as described elsewhere [23]. Briefly, the small and/or large intestine were isolated, rinsed with PBS and opened longitudinally. Mucus was removed by treatment with DTT for 15 min at 37°C on a shaker. Having washed the mucosa in PBS, it was placed in HBSS/1.5 mM EDTA and tumbled for 10 min at 37°C. The supernatant was collected and the remaining mucosa was vortexed in PBS. This supernatant was also collected. Pooled IECs were centrifuged with HBSS/PBS; the pellet was resuspended in FACS buffer (PBS+2% FCS+2 mM EDTA) and stained with anti-CD45 APC antibody (BD Biosciences, Heidelberg, Germany) to deplete hematopoietic cells [24]. IECs were sorted with a MoFlow cell sorter (Cytometry, Fort Collins, CO, USA).

**RNA isolation and expression analysis**

To analyze ZO-1 and ZO-2 mRNA expression in murine IECs, total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) with on-column DNase digestion using the RNease-Free DNase set (Qiagen). Isolated mRNA was reverse transcribed with 200 U Superscript II® (Invitrogen, Karlsruhe, Germany), oligo dT- and random hexamer primers (Invitrogen). PCR was performed using the following primers: ribosomal protein 9 (RPS9) mouse (mm) sense primer CTG GAC GAG GGC AAG ATG AAG C, RPS9 mm anti-sense primer TGA CTG TGG CGG ATG AGC ACA; ZO-1 mm sense primer TTT TTG ACA GGG GGA GTG G, ZO-1 mm anti-sense primer TGC TGC AGA GGT CAA AGT TCA AG; ZO-2 mm sense primer CTCA GAC CCC CAG AGC CCC AGA AA, ZO-2 mm anti-sense primer TCG CAG GAG TCC AGG CAT ACA AG. Quantitative real-time RT-PCR was done with the GeneAmp 5700 Sequence Detection System (Perkin Elmer, Rodgau-Jügesheim, Germany) using Brilliant SYBR Green QPCR Core Reagent Kit (Stratagene, Heidelberg, Germany). RPS9 served as control.

**Western blot analysis**

To examine the ZO-1 protein expression in IECs, lysates of sorted cells from colonized gnotobiotic mice were homogenized and

---

**Figure 1. Experimental design of the DSS colitis model.** Acute colitis was induced by administration of 4–6% DSS to drinking water (DSS). (A) Group I was orally treated with PBS twice daily. Group II was given 4–6% DSS in drinking water and orally treated with PBS twice daily. Group III received 1.5–2×10^9 CFU EcN two times a day by oral application in combination with 4–6% DSS in drinking water (DSS+EcN).

doi:10.1371/journal.pone.0001308.g001
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by blotting the proteins on a PVDF membrane. After the blocking of unsaturated protein binding sites, the membrane was incubated with the primary antibody rabbit anti-ZO-1 (Zymed, South San Francisco, CA, USA) or rabbit anti-β actin (Sigma-Aldrich, Taufkirchen, Germany) and the secondary antibody goat anti-rabbit IgG (Dianova, Hamburg, Germany), respectively.

**Electricphysiologic measurements**

The colonic mucosa was mounted between two chambers with an exposed area of 0.625 cm² and placed in an Ussing chamber. Parafilm “O” rings were used to minimize edge damage to the tissue where it was secured between the chamber halves. Tissues were bathed with HCO₃⁻ containing solutions on both sides which were gassed with 95% O₂/5% CO₂. The composition (in mM) was 108 NaCl, 22 NaHCO₃, 3 KCl, 1.3 MgSO₄, 2 CaCl₂, 1.5 KH₂PO₄, at pH 7.4. The serosal bath contained 10 glucose, 10 sodium pyruvate, 10⁻³ indomethacin, and 10⁻² tetrodotoxin; the luminal bath contained 8.9 mannitol and 10⁻² amiloride (to block potential amiloride-sensitive Na⁺ channels). Short-circuit current (Isc), potential difference (PD) and tissue resistance (R) were recorded using the Mussler 6-channel voltage clamp system (Mussler, Aachen, Germany). ²²Na resistance (R) were recorded using the Mussler 6-channel voltage clamp system (Mussler, Aachen, Germany).

Radioactivity was determined in a liquid scintillation counter, and the first and second flux period after forskolin and after glucose. There were no statistically significant differences between the values obtained in the first and second period after glucose. For the presented results, we used the values for Isc represent the average value of the 15-minute period.

**Measurement of colonic epithelial permeability**

Animals were maintained with free access to food and water. Induction of anesthesia was achieved by the administration of 10 µl/g intraperitoneal haloperidol/midazolam/fentanyl cocktail (haloperidol 12.5 mg/kg, fentanyl 0.925 mg/kg and midazolam 5 mg/kg body weight). The lower abdomen was opened by one small central incision, and a small polyethylene tube (PE100) with a distal flange was advanced to the proximal colon (immediately after the cecum), and secured by a ligature that served as inlet tube. A PE200 flanged tubing was inserted through the rectum and secured by ligature to allow for drainage through the rectum. The isolated colon segment with an intact blood supply was gently subjected to 4% paraformaldehyde, washed extensively and blocked with porcine serum. Subsequently, the sections were incubated with the primary antibody rabbit anti-ZO-1 (Zymed) followed by incubation with a Cy3 labeled secondary goat anti-rabbit IgG antibody (Jackson Immunoresearch, Cambridgeshire, UK). The sections were then dried, covered with gelatine and visualized by fluorescence microscopy. Radioactivity was determined in a liquid scintillation counter, and the first and second flux period after forskolin and after glucose. There were no statistically significant differences between the values obtained in the first and second period after glucose. For the presented results, we used the values for Isc represent the average value of the 15-minute period.

**Immunofluorescence**

Tissue sections were fixed with 4% paraformaldehyde, washed extensively and blocked with porcine serum. Subsequently, the sections were incubated with the primary antibody rabbit anti-ZO-1 (Zymed) followed by incubation with a Cy3 labeled secondary goat anti-rabbit IgG antibody (Jackson Immunoresearch, Cambridgeshire, UK). The sections were then dried, covered with gelatine and visualized by fluorescence microscopy.

**Statistical analysis**

Statistical analysis was performed with Origin 7.5 software (OriginLab, Northampton, MA, USA). For analysis of numeric values, the one-tailed analysis of variance and the Student’s t-test were used. A p-value of <0.05 was considered significant. Error bars represent the standard error of the mean.

**RESULTS**

**ZO-1 mRNA and protein expression are elevated in gnotobiotic mice colonized with EcN**

In order to investigate the impact of a single bacterial species on host IEC gene expression, we established a model for colonization of gnotobiotic mice with EcN and E. coli MG1655. To further investigate the in vivo impact of EcN on the epithelial barrier, primary IECs from the intestine of gnotobiotic mice were isolated and sorted by FACS resulting in an IEC population with greater than 94% purity (Figure 2A). ZO-1 is a TJ protein which has been described to play an important role in the prevention of intestinal barrier disruption by probiotics. Therefore, we investigated whether EcN differentially regulates ZO-1 mRNA expression in vivo. As depicted in figure 2B colonization of gnotobiotic mice with EcN resulted in a specific up-regulation of ZO-1 mRNA in IECs (p<0.05). To confirm these data at protein level, sections of ileum and colon from gnotobiotic control mice and animals colonized with EcN were stained with anti-ZO-1 antibody followed by a fluorescence-labeled secondary antibody (Figure 3A). Comparison of ZO-1 staining along the surface of the crypts revealed only a slight increase of ZO-1 protein in IECs of mice colonized with EcN. To further analyze the up-regulated ZO-1 expression at protein level, isolated IECs were investigated by Western blotting. In comparison to IECs isolated from control mice and those colonized with E. coli MG1655, IECs from EcN treated animals showed a markedly elevated expression of ZO-1 protein (Figure 3B). Thus, we could clearly demonstrate that colonization of gnotobiotic mice with EcN specifically up-regulates ZO-1 expression at the mRNA as well as at the protein level. Due to the important functional role of ZO-1 in the intestinal epithelial barrier function by EcN could at least in part be attributed to up-regulation of ZO-1. It has also been previously demonstrated that treatment of T84 cells with EcN leads to an up-regulation of ZO-1 expression at the mRNA level. Due to the important functional role of ZO-1 in the intestinal epithelial barrier function by EcN could at least in part be attributed to up-regulation of ZO-1. It has also been previously demonstrated that treatment of T84 cells with EcN leads to an up-regulation of ZO-1 in vivo [10]. In contrast to the data generated with the T84 cell line, analysis of ZO-2 mRNA expression in IECs isolated from gnotobiotic mice colonized with EcN or E. coli MG1655 did not result in an increase of ZO-2 mRNA levels (fold change <2) in vivo (Figure 2C).

**Elevated ZO-1 expression after EcN treatment in experimental colitis**

It has been shown that the impaired barrier function in IBD is associated with an altered TJ structure [7,8,25–28]. Recently it was demonstrated that EcN, used as a therapeutic for the treatment of ulcerative colitis, ameliorates acute colitis in mice [29]. These observations raised the question whether an alleviated
acute colitis as a consequence of EcN treatment may be due to its effect on the epithelial barrier. To investigate this aspect acute colitis was induced in BALB/c mice by administration of 4–6% DSS in drinking water for a period of 8 days [22]. In addition, mice were given 1.5–2 × 10^8 CFU EcN or PBS orally two times a day. In contrast to untreated control mice of group I, mice exposed to DSS (group II) developed symptoms of acute colitis with diarrhea, rectal bleeding and wasting, loosing 10% of their initial body weight within 8 days (Figure 4A). Concomitant oral administration of EcN (group III) significantly ameliorated the severity of DSS-induced colitis and the loss of body weight was reduced (6%) (p < 0.05). Healthy control mice (group I) exhibited an average colon length of 8.4 ± 1.1 cm, whereas, as a consequence of severe intestinal inflammation, the colon length of DSS treated diseased mice (group II) was reduced to 6.9 ± 1.2 cm (p < 0.001). In contrast, in DSS and EcN treated mice (group III), this colon shortening was significantly attenuated with 7.5 ± 1.5 cm (p < 0.05) (Figure 4B). Colonic inflammation is correlated with strong infiltration of hematopoietic cells into the intestine. To further elaborate the beneficial effect of EcN in DSS treated mice, FACS analysis of hematopoietic cells in the colon was performed. Consistent with the reduction in loss of body weight and colon shortening, mice treated with DSS and EcN (group III) exhibited significantly lower leukocyte infiltrates in the colon in comparison to DSS treated mice (group II) (Figure 4C).

To analyze whether the improved state of health after EcN treatment is accompanied with an increased ZO-1 expression, IECs were isolated from the colon of treated mice and analyzed for ZO-1 gene expression. IECs of mice treated with DSS and EcN showed elevated ZO-1 mRNA levels in comparison to DSS treated animals (p < 0.05) (Figure 5). Although ZO-2 mRNA was not up-regulated by EcN under healthy conditions, a slight
increase of ZO-2 mRNA could be detected in DSS mice treated with EcN (data not shown). These results further underline the beneficial effects of EcN on the intestinal barrier even under inflammatory conditions.

Electrolyte transport capacity and tissue resistance after EcN treatment in experimental colitis

In order to assess the electrolyte transport capacity and the tissue resistance (R) in acute DSS colitis, and the influence of EcN treatment on these parameters, the basal and forskolin-stimulated Isc, basal and forskolin-inhibited Na+ absorption, and the tissue-resistance R in isolated colonic mucosa of inflamed DSS treated mice (group II), DSS and EcN treated mice (group III), and healthy controls (group I) were studied. To ensure that any potential inflammation-related changes would be detected, the mucosa was neither stripped nor were the prostaglandin production or neural transmission inhibited. Interestingly, no difference was found in either the basal and forskolin-stimulated Isc (Figure 6A), or in the transmucosal electrical resistance (R)
between the different groups (data not shown). This demonstrates that in acute DSS colitis, the anion secretary capacity, which originates from the cryptal region of the colonic epithelium, is not perturbed. On the other hand, net Na\(^+\) absorption was significantly decreased in colonic mucosa of DSS and EcN treated mice (group III), and reversed to Na\(^+\) leakage into the luminal fluid in the mucosa of DSS treated mice (group II) (Figure 6B). Since the transporters for Na\(^+\) absorption are expressed in the surface colonic enterocytes, this demonstrates severe alterations in surface cell electrolyte transport following treatment with EcN.

**Reduction of colonic epithelial permeability after EcN treatment in experimental colitis**

In order to address the question whether the pronounced ZO-1 expression in EcN treated mice (group III) impacts the permeability of the colonic epithelium for transport of luminal substances, the uptake of Evans Blue into the mucosa in anesthetized mice after a short-term luminal perfusion with the dye was measured. In comparison to untreated mice (group I), a strong increase of Evans Blue uptake into the colonic mucosa of DSS treated mice (group II), and a much lesser increase into the colonic mucosa of DSS and EcN treated mice (group III) was detected (Figure 7). This demonstrates that the concomitant application of EcN during colitis induction with DSS markedly ameliorates the leakiness of the colonic epithelium.

**DISCUSSION**

The current study establishes that E. coli Nissle 1917 positively impacts the intestinal epithelial barrier in vivo in three different ways. First, EcN is capable of producing a specific up-regulation of ZO-1 expression in IECs of healthy gnotobiotic mice. When treated concomitantly with EcN, IECs of mice with DSS-induced colitis also exhibit a pronounced expression of ZO-1 mRNA. Finally, EcN provides protection against the DSS-mediated leakiness of the gut in our mouse model. Our data strongly suggest that one of the protective effects of EcN treatment on colitis prevention could be a modulation of tight junctional integrity which in turn leads to preserved intestinal barrier function against noxious or infectious agents.

Critical for the development of IBDs are imbalances in mucosal immunity as well as a disturbed function of the epithelial barrier, which leads to a marked infiltration of luminal microflora [30]. Moreover, in the majority of cases, gastrointestinal diseases develop from the disruption of the intestinal epithelial barrier by enteropathogenic bacteria that alter the cellular cytoskeleton [31,32] or affect specific tight junction proteins like ZO-1 [33]. In the past years, probiotics have been shown to be effective in the treatment of mild to moderately active IBD [10] and to reduce inflammation in animal models of colitis [29,34–36]. Three large clinical trials have investigated the therapeutic efficacy of EcN in maintaining remission of UC. EcN was reported to be as efficacious as standard medication in preventing the relapse of UC [12–14]. Although the mechanisms leading to relapses in the pathogenesis of IBDs have not yet been clarified, there is growing evidence that increased intestinal permeability plays a key role. This report is the first to demonstrate a direct influence of the therapeutic EcN on expression of the TJ associated molecule ZO-1 under healthy and inflammatory conditions. We demonstrate that EcN specifically up-regulates ZO-1 expression both at the mRNA and at the protein level in IECs of gnotobiotic mice. Very recently, Zyrek et al. described the up-regulation of ZO-2 after EcN exposure to the T84 cell line in vitro [10]. However, in this study analysis of IECs from gnotobiotic mice colonized with EcN did not reveal a differential ZO-2 mRNA expression in vitro following EcN treatment.

In order to study functional consequences of DSS-mediated colitis and EcN treatment and also the potential significance of ZO-1 up-regulation for an enhancement of intestinal barrier function, we performed experiments aimed to assess transport and barrier function of the colonic epithelium of DSS-treated mice with and without application of EcN. To evaluate secretory and absorptive function of the colonic epithelium, we measured the basal and forskolin-stimulated Isc (which is an assessment of the electrogenic anion secretion, and its stimulation by an increase in intracellular cAMP levels), as well as net Na\(^+\) absorption before and after an increase in cAMP levels. Interestingly, after one week of DSS treatment, the acute colitis did not compromise the secretory function of the epithelium at all, but abolished the Na\(^+\) absorptive function completely. Na\(^+\) absorption is mediated by electroneutral (apical Na\(^+\)/H\(^+\) exchangers NHE3 and possibly NHE2) and electrogenic (apical Na\(^+\) channel ENaC) pathways in the colon [37]. Na\(^+\) absorptive transporters are compromised during acute colitis, and this is one major reason for diarrhea during colonic inflammation [38].

Active fluid absorption is also dependent on intact tight junctions, otherwise a phenomenon called “leak flux diarrhea” occurs [39–41]. A cytokine-induced intestinal barrier dysfunction via a leak flux mechanism has recently been proposed by Schmitz et al. as potential cause for non-infectious diarrhea in HIV-infected patients, in addition to mucosal transformation with a consecutive malabsorptive mechanism [42]. When cholera toxin deletion mutants of *Vibrio cholerae* were given to healthy volunteers they still developed mild diarrhea [43]. Searching for the causative agent led to the detection of the ZOT, a toxin which causes a disruption of the tight junctions in isolated intestine [44]. Later studies revealed yet another agent from *Vibrio cholerae*, the HA/protease, that specifically interferes with the tight junction proteins occludin and ZO-1 resulting in barrier disruption [45,46]. Thus, it became clear that the integrity of the tight junctions was necessary for the maintenance of an absorptive state of the gut epithelium. In addition, it was found that a disruption of the tight junctional complex allowed easier permeation of substances from the lumen [47]. Our experiments demonstrated a strongly elevated influx of Evans Blue into the colonic mucosa in the live mouse with DSS colitis which is indicative of increased gut permeability. Much less dye was bound to IECs of mice treated concomitantly with EcN. Combined with the absorptive Na\(^+\) flux in these animals, this is likely to explain the nearly normal appearance of the feces in the...
DSS plus EcN treated mice compared to the liquid stools of the mice with DSS colitis. It is feasible that the reduction of DSS-mediated downregulation of ZO-1 expression by EcN treatment is one reason for the enhanced barrier stability.

Several lines of evidence suggest that increased intestinal permeability has a central role in the pathogenesis of IBDs. For example, between 10–20% of presymptomatic CD patients have been shown to exhibit increased gut permeability [48,49]. Alteration of TJ structure in UC for instance results in impaired barrier function [40]. Localization studies in mucosal biopsies of IBD patients have revealed disappearance of key TJ proteins from intercellular junctions [26,50]. Probiotics have been shown to reduce the increased intestinal permeability in vitro [51] as well as in clinical trials [52]. Here we demonstrate for the first time that the substantially increased intestinal permeability of mice treated with DSS is significantly alleviated by simultaneous oral application of EcN. In addition, we observed an altered ZO-1 expression profile in IECs of mice with DSS-induced colitis. Recently, a study described the translocation of ZO-1 from the apical to the basolateral side in CD patients [53] indicating an alteration of ZO-1 under pathological conditions. Moreover, using a mouse colitis model, Resta-Lenert et al. have shown that the increase in intestinal permeability is associated with a decrease of occludin and ZO-1 phosphorylation [54].

However, administration of EcN in our mouse models not only diminished the clinical signs of colitis like colon shortening and weight loss, but also prevented an increase in intestinal permeability while concurrently minimizing the down-regulation of IEC ZO-1 expression. This indicates a considerable association between the severity of colitis, as evidenced by increased gut

Figure 6. Secretory and absorptive function of isolated colonic mucosa from DSS-treated mice, with and without EcN administration, and healthy controls. (A) Basal and forskolin-stimulated Isc in DSS treated (group II n = 7), DSS+EcN (group III n = 12) and control animals (group I n = 10). The different numbers resulted from the fact that considerably more colonic segments from the DSS treated mice were so friable that they ruptured before measurements could be taken. (B) Basal and post-forskolin net Na⁺ flux rates in the three different groups. Whereas Na⁺ absorption was completely abolished in group II, active Na⁺ absorption was only partially inhibited in group III. Only in the control group I could an inhibition of Na⁺ absorption by forskolin be observed, indicating normal regulation (n = 6/group). *p<0.05
doi:10.1371/journal.pone.0001308.g006
permeability, and altered ZO-1 mRNA expression levels. It can be speculated that the rise of ZO-1 expression results in a reduced intestinal permeability by an enhanced junctional complex or a speculated that EcN augments mucosal barrier function. These in vivo results corroborate the in vitro findings from other groups by demonstrating that probiotic EcN plays an important role in the maintenance of intestinal barrier function. An improved barrier integrity elicited by EcN is an appealing explanation for the success of this probiotic in the therapy of UC and could be an important aspect in treating further human intestinal disorders, including HIV-associated diarrhea.

ACKNOWLEDGMENTS

We thank further Lothar Gröbe for FACS sorting, Marco Metzger for performing immunohistochemistry and Silvia Prettin for technical support as well as Anna Smoczek and Ina Kohn for animal care. The authors also gratefully acknowledge Michael J. Schubert for critically reading the manuscript.

Author Contributions

Conceived and designed the experiments: SU US JB FG AW. Performed the experiments: SU AS UD RE AB. Analyzed the data: SU AW. Contributed reagents/materials/analysis tools: SS AF SU WH DB GR.

REFERENCES

1. Farquhar MG, Palade GE (1963) Junctional complexes in various epithelia. J Cell Biol 17: 375–412.
2. Kapenbwa MS, Fleming SC, Sewankamo N, Serwadda D, Lucas S, et al. (1991) Altered small-intestinal permeability associated with diarrhea in human-immunodeficiency-virus-infected Caucasian and African subjects. Clin Sci (Lond) 81: 327–334.
3. Rene E, Marche C, Regnier B, Saimot AG, Valde JL, et al. (1989) Intestinal infections in patients with acquired immunodeficiency syndrome. A prospective study in 132 patients. Dig Dis Sci 34: 773–780.
4. Smith PD, Lane HC, Gill VJ, Manischewitz JF, Quinnan GV, et al. (1988) Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann Intern Med 108: 328–333.
5. Stevenson BR, Siliciano JD, Moeseker MS, Goodenough DA (1986) Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 103: 755–766.
6. Wüthrich ES, Haskins J, Stevenson BR (1999) Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3. J Biol Chem 274: 35179–35185.
7. Ma TY, Boivin MA, Ye DM, Pedram A, Said HM (2005) Mechanism of tumor necrosis factor-alpha modulation of Caco-2 epithelial tight junction barrier: Role of myosin light chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 288: G422–G430.
8. Wang F, Graham WV, Wang Y, Witzkowski ED, Schwarz BT, et al. (2005) Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 166: 409–419.
9. Gambiner B, Lowenkopf T, Apatira D (1991) Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1. Proc Natl Acad Sci U S A 88: 3460–3464.
10. Zvyrke AA, Ghion C, Helsm S, Enders C, Sonnenborn U, et al. (2007) Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCζ/π redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 9: 804–816.
11. Havenaar R, Huis in ’t Veld JHJ (1992) Probiotics: a general view. In: Wood BJ, ed (1992) The Lactic Acid Bacteria. New York: Chapman & Hall. pp 209–224.
12. Kruis W, Schutz E, Frie P, Fica B, Jüdmäger G, et al. (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853–858.
13. Kruis W, Frie P, Pokrotnieks J, Lukas M, Fica B, et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617–1623.
14. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Anon ATR (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635–639.
15. Westendorf AM, Gunther F, Deporrenmier T, Tapadar D, Hunger JK, et al. (2005) Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 43: 373–384.
16. Henker J, Laars M, Blokhin BM, Bolot YK, Maydannik VG, et al. (2007) The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhea in infants and toddlers. Eur J Pediatr 166: 311–318.
17. Dotan I, Rachmilewitz D (2005) Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol 21: 420–430.
18. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterol 125: 1620–1633.
19. Resto-Lenert S, Barrett KE (2003) Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (IEC). Gut 52: 981–997.
20. Bleich A, Sundberg JP, Smoczek A, von Waiselwski R, de Buhr MF, et al. (2007) Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. Int J Exp Pathol Nov 13: Epub ahead of print.
21. Gunzer F, Hennig-Pauck A, Waldmann KH, Mengel M (2003) Gut microbiota pigment as an animal model for oral infection with O157 and non-O157 serotypes of STEC. Methods Mol Med 73: 307–327.
22. Grabig A, Pacák D, Guzy C, Dankof A, Baumgart DC, et al. (2006) Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 74: 4075–4082.

doi:10.1371/journal.pone.0001308.g007

Figure 7. Permeability to Evans Blue in the colon of DSS treated (group II), DSS-EcN (group III) treated mice and controls (group I). The graph shows a significant increase in Evans Blue uptake into the colonic mucosa of group II mice and a strong reduction in Evans Blue uptake in group III mice to almost normal values (n = 6/group). **p < 0.001

PLoS ONE | www.plosone.org 8 December 2007 | Issue 12 | e1308
23. Roager G, Daig R, Aschenbrenner E, Vogl D, Schlotmann K, et al. (1998) Establishment of long-term primary cultures of human small and large intestinal epithelial cells. Lab Invest 78: 889–890.

24. Spyridonidis A, Schmitt-Graft A, Tomann T, Dwenger A, Folko M, et al. (2004) Epithelial tissue chimerism after human hematopoietic cell transplantation is a real phenomenon. Am J Pathol 164: 1147–1155.

25. Schirrmann G, Brüwer M, Kloz A, Schmid KW, Senninger N, et al. (1999) Transepithelial transport processes at the intestinal mucosa in inflammatory bowel disease. Int J Colorectal Dis 14: 41–46.

26. Ivanov AI, Nusrat A, Parkos CA (2004) The epithelium in inflammatory bowel disease: potential role of endocytosis of junctional proteins in barrier disruption. Nocartis Found Symp 263: 115–121.

27. Nejdfors P, Wang Q, Ekholm M, Westrom BR, Jansson O, et al. (1998) Increased colonic permeability in patients with ulcerative colitis: An in vitro study. Scand J Gastroenterol 33: 749–753.

28. Wyatt J, Vogelsang H, Hobl W, Waldhoer T, Loehr H (1993) Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 341: 1437–1439.

29. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, et al. (2004) Rapid disruption of epithelial barrier function by Salmonella typhimurium is associated with structural modification of intercellular junctions. Infect Immun 63: 356–359.

30. Jepson MA, Collares-Buzato CB, Clark MA, Hirst BH, Simmons NL (1995) Inflammatory bowel disease. N Engl J Med 347: 417–429.

31. Seidler U, Lenzen H, Cinar A, Tessema T, Bleich A et al (2006) Molecular mechanisms of disturbed electrolyte transport in intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 289: G153–G162.

32. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2002) Prevention of enterohemorrhagic Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diag Lab Immunol 11: 372–378.

33. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2004) Dislocation of tight junction proteins without F-actin disruption in inactive placebo-controlled trial. Am J Clin Nutr 85: 816–823.

34. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2005) Dislocation of tight junction proteins without F-actin disruption in inactive placebo-controlled trial. Am J Clin Nutr 85: 816–823.

35. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2005) Dislocation of tight junction proteins without F-actin disruption in inactive placebo-controlled trial. Am J Clin Nutr 85: 816–823.

36. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2005) Dislocation of tight junction proteins without F-actin disruption in inactive placebo-controlled trial. Am J Clin Nutr 85: 816–823.

37. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2005) Dislocation of tight junction proteins without F-actin disruption in inactive placebo-controlled trial. Am J Clin Nutr 85: 816–823.

38. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2005) Dislocation of tight junction proteins without F-actin disruption in inactive placebo-controlled trial. Am J Clin Nutr 85: 816–823.

39. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2005) Dislocation of tight junction proteins without F-actin disruption in inactive placebo-controlled trial. Am J Clin Nutr 85: 816–823.

40. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2005) Dislocation of tight junction proteins without F-actin disruption in inactive placebo-controlled trial. Am J Clin Nutr 85: 816–823.